Changes in weight and lipogram in

patients switching from TEE to TLD in a

real-world clinic setting

Student name:
Student number:
Staff number:
Degree:

Supervisor 1: Dr Lyle Murray, MBChB, MMed, DPhil, FCP (SA), Cert ID Phys

(SA), Dip HIV Man, DTMH

Consultant in Infectious Disease at Charlotte Maxeke Johannesburg Academic

Hospital and Lecturer at the University of the Witwatersrand.

1
1 INTRODUCTION............................................................................................2
1.1 Changes in weight during HIV disease and treatment..............................2
1.1.1 Changes in weight during untreated HIV disease.....................................2
1.1.2 Changes in weight on antiretroviral therapy...............................................3
1.2 Changes in lipogram during HIV disease and treatment..........................3
1.2.1 Changes in lipogram during untreated HIV disease.................................3
1.2.2 Changes in lipogram on antiretroviral therapy...........................................3
2 AIMS AND OBJECTIVES..............................................................................3
2.1 Hypothesis.......................................................................................................3
2.2 Objectives........................................................................................................3
3 METHODS......................................................................................................4
3.1 Study design....................................................................................................4
3.2 Study participants...........................................................................................4
3.3 Data analysis...................................................................................................4
4 ETHICS...........................................................................................................4
5 TIMELINE FOR COMPLETION....................................................................4
6 FUNDING........................................................................................................5
6.1 Proposed study budget..................................................................................5
7 DATA SHARING............................................................................................5
8 REFERENCES...............................................................................................5
9 APPENDICES.................................................................................................5
9.1 Appendix 1.......................................................................................................5
9.2 Appendix 2.......................................................................................................5

1 INTRODUCTION

(This section should really be an introductory summary overview of the topic in

broad terms – it may help to write it last)

(Culminating in…)

In this study we aim to …

1.1 Changes in weight during HIV disease and treatment

1.1.1 Changes in weight during untreated HIV disease

 What happens to a patients weight during HIV disease

 What are the mechanisms for these changes
 What are the risk factors?
 What impact does this have on comorbidities?

2
 1.1.2 Changes in weight on antiretroviral therapy

 General changes
 Risk factors
 Efavirenz
 Dolutegravir

1.2 Changes in lipogram during HIV disease and treatment

1.2.1 Changes in lipogram during untreated HIV disease

 What are the common changes in the lipid profile?

 What are the mechanisms for this change?
 What are the risk factors?
 What impacts result from these changes
1.2.2 Changes in lipogram on antiretroviral therapy

 General changes
 Risk factors
 Efavirenz
 Dolutegravir

2 AIMS AND OBJECTIVES

The aim of this study is to investigate …

2.1 Hypothesis

2.2 Objectives

In order to investigate …I aim to:

1.

2.

3
3 METHODS

3.1 Study design

3.2 Study participants

3.3 Data analysis

Analyses will be carried out using..... To…, Fisher's exact tests will be

implemented, and odds ratios (OR) and 95% confidence intervals (CI)

determined. Two-sided tests will be used and the level of statistical

significance for all analyses will be set at P< 0.05.

4 ETHICS

5 TIMELINE FOR COMPLETION

Aug Sep Oct Nov Dec Jan Feb Mar Apr Jun Jul

Literature review

Protocol preparation

Protocol

assessment

Ethics application

Data collection

4
Data analysis

Writing up

Submission

6 FUNDING

6.1 Proposed study budget

7 DATA SHARING

8 REFERENCES

9 APPENDICES

9.1 Appendix 1.

9.2 Appendix 2